US009636366B2

(12) **United States Patent**
Herranz et al.

(10) **Patent No.: US 9,636,366 B2**
(45) **Date of Patent: May 2, 2017**

(54) **BACTEROIDES CECT 7771 AND THE USE THEREOF IN THE PREVENTION AND TREATMENT OF EXCESS WEIGHT, OBESITY AND METABOLIC AND IMMUNOLOGICAL ALTERATIONS**

(71) Applicant: **Consejo Superior de Investigaciones Científicas**, Madrid (ES)

(72) Inventors: **Yolanda Sanz Herranz**, Valencia (ES); **Paola Gauffin Cano**, Valencia (ES); **Yolanda Arlette Santacruz**, Valencia (ES); **Ángela Moya Pérez**, Valencia (ES); **Moisés Laparra Llopis**, Valencia (ES)

(73) Assignee: **Consejo Superior de Investigaciones Científicas**, Madrid (ES)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **14/403,930**

(22) PCT Filed: **May 16, 2013**

(86) PCT No.: **PCT/ES2013/070309**
§ 371 (c)(1),
(2) Date: **Apr. 10, 2015**

(87) PCT Pub. No.: **WO2013/175038**
PCT Pub. Date: **Nov. 28, 2013**

(65) **Prior Publication Data**

US 2015/0216913 A1 Aug. 6, 2015

(30) **Foreign Application Priority Data**

May 25, 2012 (ES) 201230796

(51) **Int. Cl.**

A61K 35/74	(2015.01)
A61K 45/06	(2006.01)
C12N 1/20	(2006.01)
C12R 1/01	(2006.01)
A23C 9/152	(2006.01)
A61K 35/741	(2015.01)

(52) **U.S. Cl.**
CPC ***A61K 35/74*** (2013.01); ***A23C 9/152*** (2013.01); ***A61K 35/741*** (2013.01); ***A61K 45/06*** (2013.01); ***C12N 1/20*** (2013.01); ***C12R 1/01*** (2013.01)

(58) **Field of Classification Search**
CPC A61K 35/74; A61K 35/741; A61K 45/06; A61K 9/00; C12N 1/20
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2009/0110664 A1 4/2009 Moore

FOREIGN PATENT DOCUMENTS

CA	2810698	A1	3/2012
EP	2359838	A1	8/2011
WO	WO-2008/076696	A2	6/2008
WO	WO-2009/055362	A1	4/2009

OTHER PUBLICATIONS

Renouf et al 2011, J Nutr. 141(6):1120-6.*
Hong et al 2008, Appl. Environ. Microbiol. vol. 74 No. 9 2882-2893.*
Marhoffer et al., "Impairment of Polymorphonuclear Leukocyte Function and Metabolic Control of Diabetes," Diabetes Care, vol. 15, No. 2 (1992).
Musso et al., "A Meta-Analysis of Randomized Trials for the Treatment of Nonalcoholic Fatty Liver Disease," Hepatology, vol. 52, No. 1, pp. 80-104 (2010).
Turnbaugh et al., "An Obesity-Associated Gut Microbiome with Increased Capacity for Energy Harvest," Nature, vol. 444, pp. 1027-1031 (2006).
Cani et al., Interplay between obesity and associated metabolic disorders: new insights into the gut microbiota, Curr. Opin. Pharmacol., 9(6):737-43 (2009).
Chang et al., Decreased cell-mediated immunity in patients with non-insulin-dependent diabetes mellitus, Diabetes Res. Clin. Pract., 28(2):137-46 (1995).
Delahooke et al., Tumor necrosis factor induction by an aqueous phenol-extracted lipopolysaccharide complex from *Bacteroides* species, Infect. Immun., 63(3):840-6 (1995).
Gerozissis, Brain insulin and feeding: a bi-directional communication, Eur. J. Pharmacol., 490(1-3):59-70 (2004).
Griffin Cano et al., Bacteroides uniformis CECT 7771 ameliorates metabolic and immunological dysunction in mice with high-fat-diet induced obesity, PLoS One, 7:1-16 (2012).
International Search Report and Written Opinion (Spanish and English), corresponding International Application No. PCT/ES2013/070309, mailed Oct. 9, 2013.

(Continued)

Primary Examiner — Padma V Baskar
(74) *Attorney, Agent, or Firm* — Marshall, Gerstein & Borun LLP

(57) **ABSTRACT**

The invention relates to a strain of *Bacteroides uniformes* with registration number CECT 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products. The invention further relates to the use of a strain of *Bacteroides uniforms*, preferably CECT 7771, or of the cellular constituents, metabolites and/or secreted molecules of said strain, or of a composition comprising same, for the prevention and/or treatment of alterations such as excess weight, obesity, adipocyte hypertrophy, hepatic steatosis or fatty liver, dyslipidemia, hyperglycemia, insulin resistance and diabetes, metabolic syndrome, hypertension, cardiovascular diseases, dysfunction of the immune system, reduced defenses against infections, and imbalance in the composition of the intestinal microbiota.

8 Claims, 8 Drawing Sheets